How to buy Abcam (ABCM) stock

Abcam plc is a biotechnology business based in the US. Abcam shares (ABCM) are listed on the NASDAQ and all prices are listed in US Dollars. Abcam employs 1,600 staff and has a trailing 12-month revenue of around 0.00.

Abcam stock price (NASDAQ: ABCM)

Use our graph to track the performance of ABCM stocks over time.

Abcam shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$20.10
52-week range	$17.14 - $24.69
50-day moving average	$18.90
200-day moving average	$20.71
Wall St. target price	$1,618.36
PE ratio	N/A
Dividend yield	$0 (0%)
Earnings per share (TTM)	N/A

Buy Abcam shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Abcam stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Abcam plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Abcam price performance over time

Historical closes compared with the close of $20.1 from 2021-05-28

1 week (2021-07-16)	N/A
1 month (2021-06-25)	4.69%
3 months (2021-04-27)	-4.96%
6 months (2021-01-23)	N/A

1 year (2020-07-23)	N/A
2 years (2019-07-23)	N/A
3 years (2018-07-23)	N/A
5 years (2016-07-23)	N/A

Is Abcam under- or over-valued?

Valuing Abcam stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcam's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abcam's EBITDA

Abcam's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $51.9 million.

The EBITDA is a measure of a Abcam's overall financial performance and is widely used to measure a its profitability.

To put Abcam's EBITDA into context you can compare it against that of similar companies.

• Gilead Sciences (GILD.US): USD$13.3 billion
• GlaxoSmithKline (GSK.US): USD$9.7 billion
• Novartis (NVS.US): USD$17.3 billion
• Regeneron Pharmaceuticals (REGN.US): USD$4 billion

Abcam financials

Revenue TTM	$269.3 million
Operating margin TTM	12.63%
Gross profit TTM	$180.2 million
Return on assets TTM	2.94%
Return on equity TTM	-0.37%
Profit margin	-0.71%
Book value	$2.87
Market capitalisation	$4.1 billion

TTM: trailing 12 months

Shorting Abcam shares

There are currently 95,808 Abcam shares held short by investors – that's known as Abcam's "short interest". This figure is 27.4% down from 131,957 last month.

There are a few different ways that this level of interest in shorting Abcam shares can be evaluated.

Abcam's "short interest ratio" (SIR)

Abcam's "short interest ratio" (SIR) is the quantity of Abcam shares currently shorted divided by the average quantity of Abcam shares traded daily (recently around 290327.27272727). Abcam's SIR currently stands at 0.33. In other words for every 100,000 Abcam shares traded daily on the market, roughly 330 shares are currently held short.

To gain some more context, you can compare Abcam's short interest ratio against those of similar companies.

• Gilead Sciences (GILD.US): 3.52
• GlaxoSmithKline (GSK.US): 2.85
• Novartis (NVS.US): 3.95
• Regeneron Pharmaceuticals (REGN.US): 1.71

However Abcam's short interest can also be evaluated against the total number of Abcam shares, or, against the total number of tradable Abcam shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abcam's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Abcam shares in existence, roughly 0 shares are currently held short) or 0.0005% of the tradable shares (for every 100,000 tradable Abcam shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abcam.

Find out more about how you can short Abcam stock.

Abcam share dividends

We're not expecting Abcam to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (4.02% forward annual dividend yield)
• GlaxoSmithKline (GSK.US) (2.03% forward annual dividend yield)
• Novartis (NVS.US) (3.77% forward annual dividend yield)

Abcam share price volatility

Over the last 12 months, Abcam's shares have ranged in value from as little as $17.14 up to $24.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abcam's is 0.5557. This would suggest that Abcam's shares are less volatile than average (for this exchange).

To put Abcam's beta into context you can compare it against those of similar companies.

• Gilead Sciences (GILD.US): 0.3955
• GlaxoSmithKline (GSK.US): 0.3983
• Novartis (NVS.US): 0.5132
• Regeneron Pharmaceuticals (REGN.US): 0.185

Abcam overview

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom. .

Frequently asked questions

What percentage of Abcam is owned by insiders or institutions?
Currently 0.002% of Abcam shares are held by insiders and 9.446% by institutions. How many people work for Abcam?
Latest data suggests 1,600 work at Abcam. When does the fiscal year end for Abcam?
Abcam's fiscal year ends in June. Where is Abcam based?
Abcam's address is: Discovery Drive, Cambridge, United Kingdom, CB2 0AX What is Abcam's ISIN number?
Abcam's international securities identification number is: US0003802040